Sequencing Later-Line CRC Tx
Optimizing the Timing and Sequencing of Regorafenib and TAS-102 for Patients With Metastatic Colorectal Cancer

Released: April 29, 2021

Expiration: April 28, 2022

Joleen Hubbard
Joleen Hubbard, MD
John L. Marshall
John L. Marshall, MD

Activity

Progress
1
Course Completed

In this episode, Joleen Hubbard, MD, and John L. Marshall, MD, discuss use of the later-line treatment options regorafenib and TAS-102 for patients with mCRC, with topics including:

  • Key data supporting the clinical use of these agents
  • Optimal sequencing and timing of use
  • Dosing considerations
  • Key adverse events

Presenters:

Joleen Hubbard, MD
Associate Professor
Gastrointestinal Oncologist
Medical Oncology
Mayo Clinic
Rochester, Minnesota

John L. Marshall, MD
Chief, Division of Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC